These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Efficacy of sotalol in idiopathic ventricular arrhythmia originating in the right ventricular outflow tract].
    Author: Maia IG, Seixas TN, Costa AM, Peres AK, Magalhães Júnior A, Sá R, Alves PA.
    Journal: Arq Bras Cardiol; 1994 Jul; 63(1):59-63. PubMed ID: 7857216.
    Abstract:
    PURPOSE: To evaluate the effects of sotalol in patients (pts) with idiopathic ventricular arrhythmias (VT) from right ventricular outflow tract. METHODS: Eighteen pts with VT were enrolled (five with monomorphic repetitive ventricular tachycardia - MRVT). Pts were submitted to a double-blind crossover randomized study (placebo vs. 320 mg/po/d/sotalol; four weeks each), after a wash-out control period. Holter recording were recorded in control and placebo and drug periods. Eligible pts have > 50/h isolated ventricular premature beats (VPB) in control, with or without paired VPB or nonsustained VT (NSVT- > 3 beats, > 100bpm). Drug efficacy criteria was: > 75% reduction in isolated VPB and > 90% of paired VPB or NSVT. The effects of the drug on uncorrected QT interval was evaluated and also on circadian rhythm of VT through the hourly pNN50/VPB ratios. Values are given as mean +/- SD. Three recordings were compared by using paired Student's "t" test. Statistical significance was assumed for p < 0.05. RESULTS: Differences between control and placebo were NS. Drug was effective in 61% of pts, reducing the 3 types of ET (VPB: placebo = 23.508 +/- 34.537; drug: 975 +/- 1357; paired placebo = 443 +/- 587; drug = 9 +/- 20). The drug was evaluated in 4 pts with MRVT, reducing all ectopic events, with efficacy of 60% over VPB and paired and 80% over NSVT (VPB: placebo = 52.639 +/- 42.207; drug: 1631 +/- 2062; paired: placebo = 796 +/- 754; drug: 20 +/- 30; NSVT: placebo = 4287 +/- 6343; drug: 9 +/- 11). Mean QT interval was 0.40 +/- 0.01s in control and 0.50 +/- 0.04s in the drug period, with no correlation between duration and efficacy. Sotalol modified the circadian rhythm of VPB in the non-responders group, mainly during the morning. CONCLUSION: Sotalol was effective in control of VT, mainly the MRVT. Its effect on VPB circadian rhythm may independently contribute to the overall efficacy profile and myocardial protective effect of this drug.
    [Abstract] [Full Text] [Related] [New Search]